Bonnie L. Smith

Associate

巴黎 + 33.1.56.59.46.60

聯絡

*Share

Bonnie Smith practices in the area of general corporate and securities law, focusing on capital markets, particularly with respect to U.S. securities law matters. She advises companies and financial institutions on a wide array of cross-border capital markets transactions, including equity and debt offerings, initial public offerings (IPOs), follow-on offerings, at-the-market (ATM) programs, U.S. shelf takedowns, spin-offs, public and private placements, and dual listings. Bonnie also counsels public companies on day-to-day corporate governance issues and compliance with reporting obligations under U.S. and French laws, including on environmental, social, and governance (ESG) and equity incentive and compensation plans.

Among the notable issuer clients Bonnie has worked with are Sanofi on its ongoing SEC compliance and its U.S. shelf program and related notes offerings; Orange on a 144A notes offering and its delisting from the NYSE and deregistration with the SEC; Innate Pharma on its ongoing SEC compliance and ATM program; and EDAP TMS on ongoing securities compliance and equity offerings. Bonnie also has advised issuers on various capital markets transactions, including representing Cellectis, Carmat, and the Kingdom of Belgium, and on the listing of EUROAPI (Sanofi's spin-off).

Prior to joining Jones Day, Bonnie practiced at an international law firm in Paris.

執業經驗

  • Orange completes US$6 billion Notes offering across five tranchesJones Day advised Orange, the global telecommunications and digital services provider, on an inaugural Rule 144A offering of US$6 billion of Notes across five tranches.
  • Sanofi successfully completes US$3 billion Notes offeringJones Day advised Sanofi, the global biopharma group, on its successful offering of US$3 billion public offering of Notes across five tranches.
  • Sanofi to separate its consumer healthcare business, OpellaJones Day acted as securities law counsel in the separation of Opella, Sanofi's consumer healthcare business, and the sale of a 50% controlling stake to CD&R.
  • Financial institutions complete benchmark €5 billion 3.450% OLO by Kingdom of BelgiumJones Day assisted the financial institutions in connection with the issuance of a 17-year benchmark €5 billion 3.450% OLO (the “OLO 104”) by the Kingdom of Belgium.
  • Innate Pharma S.A. receives up to $7.9 million investment from The Institute for Follicular Lymphoma InnovationJones Day advised Innate Pharma S.A. in connection with an up to $7.9 million investment from The Institute for Follicular Lymphoma Innovation (IFLI).
  • Orange voluntarily delists from NYSE by successful consent solicitation and voluntarily deregisters with U.S. Securities and Exchange CommissionJones Day advised Orange, S.A., a leading telecommunications operator and digital service provider serving 287 million customers, on its voluntary delisting of its American Depositary Shares from the New York Stock Exchange (“NYSE”) and voluntary deregistration from the U.S. Securities and Exchange Commission, including its successful consent solicitation in relation to its US$2.5 billion outstanding 30-year Notes due 2031.
  • Financial institutions complete benchmark €7 billion 2.70% OLO by Kingdom of BelgiumJones Day assisted the financial institutions in connection with the issuance of a five-year benchmark €7 billion 2.70% OLO (the “OLO 102”) by the Kingdom of Belgium.
  • Amadeus FiRe completes buyback tender offerJones Day advised Amadeus FiRe AG in connection with a public fixed price share buyback tender offer to its shareholders for acquiring own shares; the company, a German specialized personnel service provider, is listed on the Frankfurt Stock Exchange (Prime Standard).
  • Median Technologies completes €11.6 million equity fundraising and places €10 million convertible bond to U.S. investorJones Day represented Median Technologies SA in connection with its (i) equity fundraising of €11.6 million outside of the United States pursuant to Regulation S, including through a public offering in France to retail investors via the PrimaryBid website and a private placement through an accelerated bookbuilding process, and (ii) placement of a €10 million convertible bond to a U.S. investor.
  • OakNorth finances Heartwood CollectionJones Day advised OakNorth Bank plc on its financing for leading UK hospitality and pub group Heartwood Collection.
  • BNP Paribas, Bryan Garnier, and Natixis complete €141 million capital increase of CarbiosJones Day advised BNP Paribas, Bryan Garnier, and Natixis in connection with the €141 million capital increase with shareholders' preferential subscription rights of Carbios, a biotech company specialized in the development and industrialization of biological technologies used for plastic and textiles recycling.
  • Innate Pharma S.A. establishes at-the-market program for up to US$75 million in United StatesJones Day represented Innate Pharma S.A., as U.S. counsel, in connection with the establishment of a new at-the-market (ATM) program for up to US$75 million in the United States, including filing a prospectus with the U.S. Securities & Exchange Commission for registered shares on a Form F-3 shelf registration statement.
  • Voltalia completes €490 million capital increase with shareholders' preferential subscription rightsJones Day advised Voltalia S.A. in the €490 million capital increase with shareholders’ preferential subscription rights on the regulated market of Euronext in Paris.
  • EDAP completes follow-on public offering of American Depositary SharesJones Day represented EDAP TMS, a global leader in robotic energy-based therapies, in connection with its follow-on public offering of 3,066,667 American Depositary Shares (ADSs) on the Nasdaq Global Market.
  • Voltalia issues additional green bondsJones Day advised Voltalia in its offering of additional green bonds convertible into new shares and/or exchangeable for existing shares (OCEANEs Vertes) due 2025 (the “New Bonds”) for a nominal amount of approximately €50 million (the “Offering”) fully fungible with the OCEANEs Vertes issued in January 2021 for a total nominal amount of approximately €200 million due on January 13, 2025, (the “Existing Bonds”).
  • Bryan Garnier & Co Limited, Natixis, and Portzamparc complete up to €124 million IPO of Lhyfe on EuronextJones Day represented Bryan Garnier & Co Limited, Natixis, and Portzamparc (BNP Paribas Group), as joint lead managers and joint bookrunners, in connection with the up to €124 million initial public offering of Lhyfe on the regulated market of Euronext in Paris.
    •

    May 2026 Newsletters

    International Capital Markets Update | Spring 2026

    *Before sending, please note:

    *Information on www.jonesday.com is for general use and is not legal advice. The mailing of this email is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Anything that you send to anyone at our Firm will not be confidential or privileged unless we have agreed to represent you. If you send this email, you confirm that you have read and understand this notice.